These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25862897)

  • 21. Everolimus.
    Hasskarl J
    Recent Results Cancer Res; 2014; 201():373-92. PubMed ID: 24756805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors.
    Kaymakcalan MD; Je Y; Sonpavde G; Galsky M; Nguyen PL; Heng DY; Richards CJ; Choueiri TK
    Br J Cancer; 2013 Jun; 108(12):2478-84. PubMed ID: 23736025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
    He Q; Lin C; Ji S; Chen J
    Am J Med Sci; 2012 Dec; 344(6):491-7. PubMed ID: 22902868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis.
    Yamanaka K; Petrulionis M; Lin S; Gao C; Galli U; Richter S; Winkler S; Houben P; Schultze D; Hatano E; Schemmer P
    Cancer Med; 2013 Dec; 2(6):862-71. PubMed ID: 24403259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
    Ranpura V; Hapani S; Chuang J; Wu S
    Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
    Gabardi S; Baroletti SA
    Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Józwiak S; Stein K; Kotulska K
    Future Oncol; 2012 Dec; 8(12):1515-23. PubMed ID: 23231513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis.
    Gomez-Fernandez C; Garden BC; Wu S; Feldman DR; Lacouture ME
    Eur J Cancer; 2012 Feb; 48(3):340-6. PubMed ID: 22206873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.
    Rugo HS; Hortobagyi GN; Yao J; Pavel M; Ravaud A; Franz D; Ringeisen F; Gallo J; Rouyrre N; Anak O; Motzer R
    Ann Oncol; 2016 Mar; 27(3):519-25. PubMed ID: 26759276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2014 Dec; 14(12):1529-36. PubMed ID: 25159115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.
    Lebwohl D; Anak O; Sahmoud T; Klimovsky J; Elmroth I; Haas T; Posluszny J; Saletan S; Berg W
    Ann N Y Acad Sci; 2013 Jul; 1291():14-32. PubMed ID: 23659703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
    Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE
    Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology.
    Ravaud A; Urva SR; Grosch K; Cheung WK; Anak O; Sellami DB
    Eur J Cancer; 2014 Feb; 50(3):486-95. PubMed ID: 24332451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials.
    Wang Q; Qi Y; Zhang D; Gong C; Yao A; Xiao Y; Yang J; Zhou F; Zhou Y
    Tumour Biol; 2015 May; 36(5):3471-82. PubMed ID: 25542231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials.
    Zhan P; Wang Q; Qian Q; Yu LK
    Chin Clin Oncol; 2012 Dec; 1(2):19. PubMed ID: 25841397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening.
    Trelinska J; Dachowska I; Kotulska K; Fendler W; Jozwiak S; Mlynarski W
    Anticancer Drugs; 2015 Apr; 26(4):437-42. PubMed ID: 25719621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment-related mortality with everolimus in cancer patients.
    Wesolowski R; Abdel-Rasoul M; Lustberg M; Paskell M; Shapiro CL; Macrae ER
    Oncologist; 2014 Jun; 19(6):661-8. PubMed ID: 24794158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.